Executive Committee: Absci Corporation

Manager
Positions heldSince
Sean McClain

Sean McClain

36 year

Chief Executive Officer 2011-07-31
Founder 2010-12-31
Charles Romano

Charles Romano

Chief Tech/Sci/R&D Officer 2025-07-31
Jeanne Schreuder

Jeanne Schreuder

Human Resources Officer 2026-03-31
Ransi Somaratne

Ransi Somaratne

Chief Tech/Sci/R&D Officer 2026-03-02
Shelby Walker

Shelby Walker

51 year

General Counsel 2024-05-31
Zachariah Jonasson

Zachariah Jonasson

53 year

Director of Finance/CFO 2023-08-30
Treasurer 2023-08-30
Alexander Khan

Alexander Khan

Investor Relations Contact -
Wen Sha

Wen Sha

Human Resources Officer 2025-12-31
Todd Bedrick

Todd Bedrick

Comptroller/Controller/Auditor 2022-05-31

Composition of the Board of Directors: Absci Corporation

Director
CommitteesSince
Frans van Houten

Frans van Houten

66 year

Audit Committee
Governance Committee 2025-03-06
Nominating Committee 2025-03-06
Governance Committee Chair
Nominating Committee Chair
Karen McGinnis

Karen McGinnis

59 year

Compensation Committee 2020-07-31
Audit Committee Chair 2020-07-31
Audit Committee 2025-07-06
Joseph Sirosh

Joseph Sirosh

57 year

Governance Committee 2025-03-31
Nominating Committee 2025-03-31
Daniel Rabinovitsj

Daniel Rabinovitsj

61 year

Audit Committee 2022-10-31
Compensation Committee Chair 2022-10-31
Mary Szela

Mary Szela

62 year

Audit Committee 2026-02-18
Compensation Committee Chair 2026-02-18
Menelas Nicolas Pangalos

Menelas Nicolas Pangalos

59 year

Compensation Committee
Sean McClain

Sean McClain

36 year

Director/Board Member 2010-12-31

Former Officers and Directors: Absci Corporation

Insider
Positions held
SinceUntil
Andreas Busch
Andreas Busch
Director/Board Member 2022-03-16 2022-10-03
Corporate Officer/Principal 2022-10-03 2026-03-30
Karin Wierinck
Karin Wierinck
Human Resources Officer 2023-02-28 2026-02-28
Amaro Taylor-Weiner
Amaro Taylor-Weiner
Corporate Officer/Principal 2023-08-31 2025-05-31
Amrit Nagpal
Amrit Nagpal
Director/Board Member 2020-09-30 2025-04-24
Independent Dir/Board Member 2020-09-30 2025-04-24
Jack Gold
Jack Gold
Sales & Marketing 2022-07-13 2024-05-31
Imad Ajjawi
Imad Ajjawi
Corporate Officer/Principal 2020-12-31 2024-03-31
Sarah Korman
Sarah Korman
General Counsel 2020-12-31 2023-09-14
Gregory Schiffman
Gregory Schiffman
Director of Finance/CFO 2020-03-31 2023-08-30
Ivana Magovcevic-Liebisch
Ivana Magovcevic-Liebisch
Director/Board Member 2020-07-31 2020-12-31
Chairman 2020-12-31 2023-06-13
Independent Dir/Board Member 2020-07-31 2023-06-13
Kate Corcoran
Kate Corcoran
Corporate Officer/Principal - 2023-04-30
James Sietstra
James Sietstra
Corporate Officer/Principal 2021-05-31 2022-10-30
Matthew Weinstock
Matthew Weinstock
Chief Tech/Sci/R&D Officer 2020-08-31 2022-10-03
Nikhil Goel
Nikhil Goel
Corporate Officer/Principal 2021-07-06 2022-09-19
Denise Dettore
Denise Dettore
Human Resources Officer 2022-07-13 -
Eli Casdin
Eli Casdin
Director/Board Member 2020-11-30 2022-07-07
Independent Dir/Board Member 2020-11-30 2022-07-07
Andreas Pihl
Andreas Pihl
Director/Board Member - 2022-05-12
Chief Operating Officer - 2022-05-12
Gustavo Mahler
Gustavo Mahler
Director/Board Member 2018-05-31 2021-05-31
Milad Alucozai
Milad Alucozai
Consultant / Advisor 2019-12-31 2020-12-31
Daniel S. Gold
Daniel S. Gold
Director/Board Member 2016-05-15 -
V. Lawlis
V. Lawlis
Director/Board Member 2016-04-30 -
Independent Dir/Board Member 2016-04-30 -
Mark Valasek
Mark Valasek
Founder 2010-12-31 -
Melissa Patterson
Melissa Patterson
Human Resources Officer - -
Tom Cordaro
Tom Cordaro
Corporate Officer/Principal - -
Penelope
Penelope
Corporate Officer/Principal - -

Age distribution of managers

Parity Men Women

Male13
Female4

Of which Executive Committee

Male7
Female2

Of which Directors

Male5
Female2
Logo Absci Corporation
Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Employees
140

Departures of Key Persons

Ivana Magovcevic-Liebisch
-
Ivana Magovcevic-Liebisch

Chairman

2020-12-31 2023-06-13

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!